ArticleInternational journal of clinical and experimental pathology2017
Downregulation of serum miR-26a predicts poor clinical outcome of papillary thyroid carcinoma.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Circulating microRNAs and Clinicopathological Findings of Papillary Thyroid Cancer: A Systematic Review.In vivo (Athens, Greece)Pooled it
- Papillary Thyroid Carcinoma Tissue miR-146b, -21, -221, -222, -181b Expression in Relation with Clinicopathological Features.Diagnostics (Basel, Switzerland) · 2021Article
- The Prognostic Value of MicroRNAs in Thyroid Cancers-A Systematic Review and Meta-Analysis.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deregulation of miRNAs has been demonstrated to play an important role in the initiation and development of many types of cancers including papillary thyroid carcinoma (PTC). Currently the role of miR-26a and its potential clinical significance for PTC remains unknown. Eighty-four PTC patients and forty healthy controls were enrolled in this study. Quantitative real-time PCR (qRT-PCR) was performed to determine the expression level of serum miR-26a in all the participants. The association between serum miR-26a expression level and clinical outcome of PTC was investigated. Serum miR-26a expression level was reduced in PTC patients compared with the healthy controls (
Indexed as
Identifiers
31966775PMC6965458W3026444519What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.